Johnson & Johnson Rated Strongly in Multi-Factor Report

Johnson & Johnson (JNJ) stands out in a recent analysis, achieving a 68% rating using the Multi-Factor Investor model. This score reflects its underlying fundamentals and stock valuation, indicating a modest level of investor interest.

Date: 20-02-2025

AI Rating: 5

Investment Insights on Johnson & Johnson

The report highlights Johnson & Johnson's (JNJ) stock performance, focusing on its ratings based on the Multi-Factor Investor model developed by Pim van Vliet. With a 68% rating, the stock qualifies as a large-cap growth option in the Biotechnology & Drugs industry, reflecting its potential but also signaling some caution since it didn't exceed the 80% threshold for strong interest.

This analysis reveals a positive market cap and standard deviation, both marked as 'PASS,' pointing to stable characteristics and low volatility, which are favorable traits for investors seeking lower risk. However, the stock’s final rank of 'FAIL' suggests it might lack certain critical elements that investors are looking for, which could dampen its attractiveness in the near term.

Key Performance Metrics

The report does not provide explicit details regarding specific financial metrics such as Earnings Per Share (EPS), Revenue Growth, Net Income, Profit Margins, Free Cash Flow (FCF), or Return on Equity (ROE). Instead, it focuses mainly on the structural assessment of JNJ based on the applied multi-factor strategy.

Furthermore, while the stock shows solid attributes related to market cap and standard deviation, the neutral ratings in twelve-month momentum and net payout yield suggest that while JNJ remains a stable and potentially rewarding investment, it may not exhibit the immediate growth investors could be seeking. The indications of high net payout yields could indicate good returns for shareholders, but the overall neutral observations suggest that caution should still be exercised.

Stocks: JNJ